A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

NCT01682863 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

614

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: QVA149
DRUG: QVA149
DRUG: QAB149
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals